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Abstract
Background: Fluid resuscitation is a cornerstone of intensive care treatment, yet there is a lack of agreement on
how various types of fluids should be used in critically ill patients with different disease states. Therefore, our goal
was to investigate the practice patterns of fluid utilization for resuscitation of adult patients in intensive care units
(ICUs) within the USA.
Methods: We conducted a cross-sectional online survey of 502 physicians practicing in medical and surgical ICUs.
Survey questions were designed to assess clinical decision-making processes for 3 types of patients who need
volume expansion: (1) not bleeding and not septic, (2) bleeding but not septic, (3) requiring resuscitation for sepsis.
First-choice fluid used in fluid boluses for these 3 patient types was requested from the respondents. Descriptive
statistics were performed using a Kruskal-Wallis test to evaluate differences among the physician groups. Follow-up
tests, including t tests, were conducted to evaluate differences between ICU types, hospital settings, and bolus volume.
Results: Fluid resuscitation varied with respect to preferences for the factors to determine volume status and
preferences for fluid types. The 3 most frequently preferred volume indicators were blood pressure, urine output,
and central venous pressure. Regardless of the patient type, the most preferred fluid type was crystalloid, followed by
5 % albumin and then 6 % hydroxyethyl starches (HES) 450/0.70 and 6 % HES 600/0.75. Surprisingly, up to 10 % of
physicians still chose HES as the first choice of fluid for resuscitation in sepsis. The clinical specialty and the practice
setting of the treating physicians also influenced fluid choices.
Conclusions: Practice patterns of fluid resuscitation varied in the USA, depending on patient characteristics, clinical
specialties, and practice settings of the treating physicians.
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Background
Fluid resuscitation is a cornerstone of intensive care
treatments, and fluid therapy is one part of a complex
strategy in hemodynamic resuscitation (Myburgh and
Mythen 2013). There is considerable debate about the
effects of fluid type, timing of administration, appropri-
ate amount of fluid, and techniques for determining
fluid responsiveness (Cherpanath et al. 2014; van Haren
and Zacharowski 2014). The principles of fluid exchange
and how they influence clinical decisions regarding fluid
type have been a major topic of interest. With approxi-
mately 1.7 million inpatient stays associated with sepsis
during 2009, sepsis has become the sixth most common
reason for hospitalization in the USA (Elixhauser et al.
2006). Thus, it is of interest to understand how physi-
cians approach fluid resuscitation in sepsis relative to
nonseptic conditions. Since 1896, Starling’s Principle of
Fluid Exchange stated that fluid movement across the
capillary wall depends on the balance between the
hydrostatic pressure gradient that pushes water outward
into the interstitial space and the colloid oncotic pressure
that pulls water inward into the vessel (Aditianingsih and
George 2014). As we come to better understand that suc-
cessful fluid resuscitation depends on the disease “context”
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(i.e., the physiological state of the patient), it becomes ap-
parent that the classic Starling’s Principle does not apply
to all situations and needs to be adapted to encompass
conditions involving systemic inflammation and vascular
barrier damage (Jacob and Chappell 2013).
In recent years, new research efforts increasingly
recognize the endothelial glycocalyx layer (EGL) as a cru-
cial determinant of vascular barrier function (Weinbaum
et al. 2007; Becker et al. 2010). The EGL acts as a filter
that generates an effective colloid oncotic pressure with
the presence of a protein-free layer in the subglycocalyx
space of the EGL. Large molecules, (e.g., albumin in col-
loid solutions) are retained inside the vessel, generating
colloid oncotic pressure in the intravascular compartment
(Myburgh and Mythen 2013; Aditianingsih and George
2014; Jacob and Chappell 2013). Small molecules (e.g.,
electrolytes in crystalloid solutions) traveling freely
through the vessel wall can draw water into the interstitial
space. Animal and human studies suggest that the EGL is
damaged in numerous systemic inflammatory states,
including trauma (Johansson et al. 2011) and sepsis
(Steppan et al. 2011), and may become compromised,
leading to interstitial edema (Weinbaum et al. 2007;
Ait-Oufella et al. 2010). In other words, colloids may
behave more like crystalloids in sepsis, and several large
studies have failed to show any benefit from colloids in
this context. On the other hand, if a patient has an intact
EGL and an intravascular volume deficit, then volume
therapy with a colloid fluid restores the intravascular vol-
ume as predicted by Starling, and far higher volumes of
crystalloids are required to achieve the same result (Rehm
et al. 2000). In this context, at least theoretically, colloids
may have advantages over crystalloids (Roger et al. 2014).
In addition, there is still on-going debate over whether
liberal or restricted fluid volume strategies would yield
more favorable clinical outcomes in critically ill patients
(Polderman and Varon 2015). What is generally accepted
is that fluid administration should be managed to
achieve zero or negative fluid balance by the time pa-
tients recover from all 4 phases of fluid resuscitation [(1)
salvage/rescue, (2) optimization, (3) stabilization, (4) de-
escalation] (Vincent and De Backer 2013; Myburgh
2015; Hoste et al. 2014; Rewa and Bagshaw 2015). The
context of where the patients are in their course of crit-
ical illness is important (Vincent and De Backer 2013).
The FIRST (James et al. 2011) and CRISTAL (Annane et
al. 2013) trials enrolled patients undergoing resuscitation
for highly severe trauma and severe hypotensive, hypo-
volemic shock, respectively, which presumably mean
those patients were in the salvage/rescue phase. On the
other hand, the SAFE (Finfer et al. 2004), CHEST
(Myburgh et al. 2012), and ALBIOS (Caironi et al. 2014)
trials enrolled patients who were mostly in the
optimization phase with lower fluid volume needs and
likely longer time interval from shock onset. Likewise,
other trials (Navarro et al. 2015; Opperer et al. 2015)
conducted in the perioperative disease context were
likely in the optimization phase.
It is important to assess how fluids are currently being
used in the USA for sepsis and other critical care condi-
tions. The objectives of this study were the following:
(A) to examine the use of different types of fluids for re-
suscitation (i.e., crystalloids, plasma-derived colloid [albu-
min], synthetic colloids [hydroxyethyl starches, HES]) in
critically ill patients in adult intensive care units within
the USA; (B) to determine whether certain patient charac-
teristics and/or practice settings have an influence on the
type of fluid utilized for resuscitation; and (C) to deter-
mine whether the fluid selected for resuscitation varies by
clinical specialties of the treating physicians.
Methods
Study design
This study is cross-sectional and collected survey data
from physicians practicing in medical and surgical ICUs
of the USA. A 10-min online survey was administered to
502 physicians to investigate the patterns of fluid
utilization in the ICU. Initial survey questions were de-
veloped by 2 of the authors (TM and CSB), finalized
through discussion and input from all authors then pre-
tested to ensure the quality of the survey. The 25-item
self-administered questionnaire (Additional file 1) ob-
tained information on preferences for fluid use in
hemodynamic management and volume status indicators
used most often to determine volume expansion needs.
The survey questions were designed to assess clinical
decision-making for 3 types of patients: “patient type 1”
needs volume expansion but is not bleeding and not sep-
tic, “patient type 2” needs volume expansion in the pres-
ence of blood loss when blood transfusion is not
indicated (adequate Hb) and the patient is not septic,
and “patient type 3” needs volume expansion for resusci-
tation in sepsis. First-choice fluid used in fluid boluses
for these 3 different types of patients was requested from
the respondents. In addition, physicians were presented
with the 3 patient scenarios sequentially and asked to
identify their first choice of fluid from a list of 5 colloid
and crystalloid solutions for volume expansion for each
patient type. The 5 types of fluids were crystalloids, 5 %
albumin, 25 % albumin, 6 % HES 450/0.70 and 6 % HES
600/0.75 (first-generation HES), and 6 % HES 130/0.4
(third-generation HES). For simplification, we will refer
to “6 % HES 450/0.70 and 6 % HES 600/0.75” as HES
450/600 and “6 % HES 130/0.40” as HES 130 throughout
the rest of this manuscript. Physicians rated the fre-
quency with which they preferred various products for
volume expansion using a 5-point scale, from “always”
to “never,” and they were also asked to indicate the bolus
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volume (milliliter) of the crystalloids and colloids that
they typically use for volume expansion. In addition,
they were asked to rate the importance of certain colloid
characteristics (e.g., more sustained volume expansion,
faster volume expansion) and nononcotic properties of
albumin (e.g., transport of metabolites, free radical scav-
enging) on the treatment decision-making process using
a 5-point scale, from “not important” to “absolutely
essential.”
In February 2015, participants were recruited from the
Research Now Healthcare physician panel. Research
Now is a company that manages a panel of physicians
who have opted to become members of the Research
Now Healthcare panel. Email invitations for participa-
tion in this study were sent from Research Now to their
physician panelists, who remained anonymous to the in-
vestigators in this study. To qualify to participate in this
survey, physicians had to specialize in anesthesiology,
surgery, critical care medicine, or pulmonology; have
been in practice for at least 2 years since residency; ro-
tate in surgical ICU, medical ICU, or an ICU accepting
a variety of patients; and treat or consult on at least 3
to 4 ICU patients per week. Physicians who worked in
cardiac, neurology, or pediatric ICUs were excluded.
Subquotas were set for each specialty to ensure that a
minimum number of completed surveys were received
from each specialty: 125 surgeons, 125 anesthesiolo-
gists, 175 critical care medicine specialists, and 75 pul-
monologists. All potential respondents were recruited
by email invitation which provided a general descrip-
tion of the survey topic and a link for interested recipi-
ents to access the online survey. Invitations were sent
to 12,435 physicians. Of these, a total of 2724 physi-
cians attempted to access the survey, making the re-
sponse rate 21.9 %. Of the 2724 who attempted to
access the survey, 502 (4.0 %) made up the final partici-
pant pool that accessed the survey, qualified via the
screening questions, and completed the survey prior to
the set quotas being reached. Each invitation contained
a unique ID that prevented any one respondent from
taking the survey more than once. The participants
were aware that the anonymous data collected in this
survey may be published.
This research project involved obtaining the opinions
of physicians about their choice for the use of various
fluids for resuscitation in 3 different hypothetical patient
situations. No patient data was obtained, and no ques-
tions were asked of the physicians that would help in
identifying them. Any physician data was de-identified.
Hence, this study was exempt from requiring institu-
tional review board review under USA Code of Federal
Regulations Title 45 Part 46.101(b)(2) by Copernicus
Group IRB, because any physician information within
the survey dataset was de-identified.
Statistical analysis
Several questions were based on 5-point scales and pro-
vided ordinal data which, by definition, are not normally
distributed. As such, descriptive statistics were per-
formed using a Kruskal-Wallis test to evaluate differ-
ences among the physician groups on the ordinal
measures. Follow-up tests were conducted to evaluate
differences between ICU types and between practice set-
tings. t tests were used to evaluate differences across ra-
tio variables (i.e., bolus volume). Statistical significance
was assessed at the alpha level of <0.05. Descriptive ana-
lyses were performed using SPSS (version 23.0). Data
analysis was done by PN.
Results
Of the 502 physicians who completed the survey, 125
(24.9 %) were anesthesiologists, 125 (24.9 %) were sur-
geons, 104 (20.7 %) practiced critical care medicine, and
148 (29.5 %) were pulmonologists (Table 1). The major-
ity of anesthesiologists and surgeons practiced in surgi-
cal ICUs, while the majority of critical care medicine
specialists and pulmonologists were from medical ICUs.
Approximately three-fourths of the physicians from each
clinical specialty practiced at nonuniversity hospitals.
The average hospital size was approximately 400 beds,
Table 1 Summary of participant characteristics
AnesthesiologistsA SurgeonS Critical care medicineC PulmonologistsP
(n = 125) (n = 125) (n = 104) (n = 148)
ICU type Surgical 58.4 % 74.4 %A – –
Medical – – 52.9 % 61.5 %
ICU accepting variety of patients 41.6 %S 25.6 % 47.1 %S 38.5 %S
Practice setting University hospital 24.8 % 28.0 % 31.7 % 26.4 %
Nonuniversity hospital 75.2 % 72.0 % 68.3 % 73.6 %
Hospital size No. of beds in the hospital 343 410 410 403
No. of ICU beds in the hospital 35 49A 39 41
Superscripts A, S, C, and P denote differences between specialties that are statistically significant at P < 0.05
ICU intensive care unit
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and the average number of ICU beds in each hospital
was about 40 beds. Physician age and gender were not
collected.
The decision-making process for fluid management
varied considerably among physicians of all clinical
specialties in this study, and there was extensive hetero-
geneity in the diagnostic approaches used to inform de-
cisions for fluid management (Fig. 1). Some of the
results provide unexpected insights into the ways in
which physicians from different backgrounds approach
ICU care. Many tests were used at varying extents by all
4 physician specialties to assess the need for volume ex-
pansion, with the 3 most frequently used indicators be-
ing blood pressure, urine output, and central venous
pressure. Our observations reflected published findings
of a Canadian survey (McIntyre et al. 2007) which re-
ported that urine output and blood pressure were also
the 2 most commonly cited resuscitation end-points for
early septic shock. To our surprise, less invasive parame-
ters, such as pulse pressure or systolic pressure variation
and plethysmographic waveform variations, were not fre-
quently used by physicians of any specialty. Of those
who chose pulse pressure or systolic pressure variation,
anesthesiologists (40 %), critical care medicine specialists
(30 %), and pulmonologists (26 %) were more than 2-
fold as likely to use these indicators as surgeons (14 %).
Overall, crystalloid fluid was the primary choice for
fluid resuscitation (Figs. 2, 3, and 4). The second most
Fig. 1 Volume status indicators and diagnostic tools used in assessing fluid needs. Superscripts A, S, C, and P denote differences between specialties
that are statistically significant at P < 0.05
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commonly chosen fluid was 5 % albumin. Only a small
fraction of physicians chose 25 % albumin as their first
choice, and, therefore, we have elected not to present
data on utilization frequency of 25 % albumin in Figs. 2,
3, and 4. Among the 4 clinical specialties of treating
physicians, there were subtle, but statistically significant,
differences in how fluids were being utilized for all 3 pa-
tient types. Data on the frequencies of utilization of vari-
ous fluids are shown in Additional file 2: Figure S1,
Additional file 3: Figure S2, and Additional file 4: Figure
S3 for the 3 patient types.
For patient type 1 who needs volume expansion in the
absence of blood loss and sepsis (Fig. 2), most physicians
(63–78 %) chose crystalloids as their first choice of intra-
venous (IV) fluids regardless of clinical specialty,
followed by 5 % albumin (9–13 %). About a quarter of
all physicians reported “often” using 5 % albumin and up
to 49 % “sometimes” use 5 % albumin (Additional file 2:
Figure S1B). HES 450/600 were chosen by 7–9 % of
physicians, while only <2 % of physicians chose HES
130. Critical care medicine specialists seemed to prefer
less crystalloids and slightly more albumin for this pa-
tient type than physicians from other specialties. In
contrast to critical care medicine specialists, anesthesi-
ologists most frequently reported “often” choosing crys-
talloids (Additional file 2: Figure S1A), “sometimes”
choosing 5 % albumin (Additional file 2: Figure S1B)
and HES 450/600 (Additional file 2: Figure S1C), but
“rarely” or “never” HES 130 (Additional file 2: Figure
S1D). Interestingly, the highest proportions of those
who “rarely” or “never” choose HES 450/600 or HES
130 were pulmonologists.
For patient type 2 who needs volume expansion in the
presence of blood loss but is not septic (Fig. 3), crystalloid
was the first choice of IV fluids (47–65 %), followed by
5 % albumin (11–24 %) and HES 450/600 (7–20 %). Less
than 5 % of physicians preferred HES 130. Although an-
esthesiologists made up the smallest proportion of those
Fig. 2 Fluid choices for patient who needs volume expansion but is not bleeding and not septic (patient type 1). First choice of intravenous
fluids in response to the question, “Which of the following is your first choice for a patient who needs volume expansion but is not bleeding and
not septic?” Superscripts A, S, C, and P denote differences between specialties that are statistically significant at P < 0.05. HES, hydroxyethyl starch
Fig. 3 Fluid choices for patient who needs volume expansion in the presence of blood loss when blood transfusion is not indicated (adequate
Hb) and patient is not septic (patient type 2). First choice of intravenous fluids in response to the question, “Which of the following is your first
choice for a patient who needs volume expansion in the presence of blood loss when blood transfusion is not indicated (adequate Hb) and
patient is not septic?” Superscripts A, S, C, and P denote differences between specialties that are statistically significant at P < 0.05. HES,
hydroxyethyl starch
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who chose crystalloids (47 %) as first choice of fluid in
this patient type, they were more likely to choose 5 % al-
bumin (24 %) than pulmonologists (11 %), and they
made up the highest proportion (41 %) of those who
“often” chose 5 % albumin compared to any other spe-
cialties (22–25 %) (Additional file 3: Figure S2B). Sur-
geons (61 %) and pulmonologists (65 %) were more
likely to prefer crystalloids than anesthesiologists (47 %).
Moreover, pulmonologists made up the highest propor-
tion of those who reported “always” choosing crystalloid
(32 %, Additional file 3: Figure S2A) but “never” HES
450/600 (43 %, Additional file 3: Figure S2C) compared
to physicians of any other specialties.
For patient type 3 who needs volume expansion for re-
suscitation in sepsis (Fig. 4), crystalloid was, again, the
first-choice of fluids (62–82 %), followed by 5 % albumin
(4–17 %). Pulmonologists (82 %) made up the highest pro-
portion of physicians who chose crystalloids as the first
choice of fluid. Similar to the patterns observed for patient
type 2 (Fig. 3), anesthesiologists (17 %) were more likely to
choose 5 % albumin as their first choice than pulmonolo-
gists (4 %), and they also made up the highest proportion
of those who “often” and “sometimes” choose 5 % albumin
(Additional file 4: Figure S3B). Surprisingly, up to 10 % of
physicians across all specialties chose HES as first-choice
fluids for this patient type despite the 2013 Food and Drug
Administration boxed warning against HES use for sepsis
due to increased mortality and severe renal injury (U.S.
Food and Drug Administration 2013). Furthermore, we
did not expect to see more physicians prefer HES 450/600
(6–10 %) over 25 % albumin (5–7 %), as the use of HES
for patients with sepsis goes against the Surviving Sepsis
Campaign (SSC) recommendations (Dellinger et al. 2013).
Among those who chose HES 130 as their first choice,
critical care medicine specialists made up the highest pro-
portion (9 %) compared to the 2–3 % of physicians from
other specialties.
When colloids were chosen as the preferred fluid for
resuscitation, the 3 reasons most frequently cited for
these decisions were the following: (1) more sustained
volume expansion (Fig. 5a); (2) faster volume expansion
(Fig. 5b); and (3) less interstitial edema (Fig. 5c). “Better
respiratory function” appeared to be of less importance
(Fig. 5d), and “less weight gain” (Fig. 5e) was the least
important factor.
Another factor affecting the decision-making process
was the practice setting from which the physicians came
(Fig. 6). Subanalysis results suggest that practice patterns
varied depending on whether a physician worked in uni-
versity vs nonuniversity hospitals. Within the dataset for
each patient type, t tests were used to assess for the sig-
nificance of the differences between proportion of physi-
cians from university and nonuniversity hospitals. To
simplify the data, we combined 5 % and 25 % albumin
into a single category named “albumin.” The same was
done for the 3 HES subtypes. Overall, most physicians
chose crystalloids as the first choice of fluid regardless of
practice setting. However, more physicians from nonuni-
versity hospitals compared to university hospitals chose
crystalloid as their first choice for volume expansion in
patient types 2 (bleeding but not septic, Fig. 6b) and 3
(septic, Fig. 6c) but not for patient type 1 (Fig. 6a). For
patient type 3, physicians from university hospitals
(21 %) preferred albumin more frequently relative to
those from nonuniversity hospitals (12 %) (Fig. 6c). This
is intriguing, as we wonder how ICU protocols at uni-
versity hospitals may have played a role in distinguishing
the behavior of this group toward treating patients with
sepsis.
When we further analyzed data of the physicians who
indicated crystalloids as the first-choice fluid based on
their clinical specialties (Table 2), we found intriguing
differences between how university and nonuniversity
hospitals would handle the 3 different types of patients.
Fig. 4 Fluid choices for patient who needs volume expansion for resuscitation in sepsis (patient type 3). First choice of intravenous fluids in response
to the question, “Which of the following is your first choice for a patient who needs volume expansion for resuscitation in sepsis?” Superscripts A, S, C,
and P denote differences between specialties that are statistically significant at P < 0.05. HES, hydroxyethyl starch
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When the data for all clinical specialties were analyzed
together, a higher proportion of physicians from nonuni-
versity hospitals (61.5 %) chose crystalloids for patient
type 2 than those from university hospitals (45.7 %);
while no difference in practice setting was found for pa-
tient types 1 and 3. When the data were analyzed based
on the 4 individual clinical specialties, statistically
significant differences were detected for only anesthesi-
ologists and surgeons; while no differences were ob-
served among critical care medicine specialists and
pulmonologists based on their practice settings. More
anesthesiologists from nonuniversity hospitals than uni-
versity hospitals preferred crystalloids as their first
choice of fluid for patient type 2 (52.1 % vs 32.3 %,
Fig. 5 Rankings of the importance of certain colloid traits when colloids are used for volume expansion. Colloid traits assessed are as follows:
(a) more sustained volume expansion; (b) faster volume expansion; (c) less interstitial edema; (d) better respiratory function; (e) less weight gain
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respectively) and for patient type 3 (73.4 % vs 51.6 %)
but not for patient type 1. Surgeons from university hos-
pitals (45.7 %) chose crystalloid as their first choice less
frequently than those from nonuniversity hospitals
(66.7 %) for patient type 2.
Interesting observations were also made regarding the
preferences for bolus volume. In general, all physicians
reported typical volume of colloid bolus (464.4 mL) as
smaller than their typical volume of crystalloid bolus
(797.4 mL). The estimated ratio of 1:1.7 for albu-
min to crystalloid volume in our study resembled previ-
ously published estimates from the SAFE study (1:1.4)
(Finfer et al. 2004) and a systematic review/meta-
regression study across 24 reports (1:1.5) (Orbegozo
Cortes et al. 2015). When bolus volume was evaluated as
a function of clinical practice settings (Table 3), results
from a one-sample t test indicated that physicians in
nonuniversity hospitals appeared to prefer a slightly lar-
ger volume of crystalloid bolus (821.7 mL) than do phy-
sicians in university hospitals (716.5 mL), although this
difference in volume was small and may not have clinical
significance in most situations. Data from VA physicians
were not included in this particular analysis due to small
sample size (n = 13). To the best of our knowledge, these
results are novel and have not been reported previously.
Discussion
This survey of 502 physicians from 4 clinical specialties
of various ICU practice settings revealed that practice
patterns in fluid resuscitation vary broadly with respect
to preferences of volume status parameters and prefer-
ences for fluid types that would be used to treat patients
who need volume expansion but are not bleeding and
not septic (patient type 1), patients who need volume ex-
pansion due to bleeding but are not septic (patient type
2), and those who need resuscitation due to sepsis (pa-
tient type 3). For volume status parameters, the 3 most
frequently preferred indicators were blood pressure,
urine output, and central venous pressure; whereas,
cardiac output, pulse pressure variation, and stroke vol-
ume may be considered to be better predictors of
hemodynamic response to fluid loading (McDermid et
al. 2014). For volume expansion, the most preferred fluid
type was crystalloid, followed by 5 % albumin, regardless
of the patient type considered. Surprisingly, up to 10 %
of physicians still chose HES as a first choice of fluid for
resuscitation in sepsis. The clinical specialties and prac-
tice settings of the treating physicians also influenced
fluid choices. Among the different physician specialties,
anesthesiologists appeared to prefer more colloids, par-
ticularly 5 % albumin, for patient types 2 and 3 than the
other physician subgroups (Figs. 3 and 4). The data sug-
gests that a greater proportion of university physicians
than nonuniversity physicians preferred colloid as a first
choice of fluids (Fig. 6).
Our finding that crystalloid was the first choice of fluid
for most physicians in the USA aligned with published
data from an international, cross-sectional survey (391
ICUs) in 2007 (Finfer et al. 2010), which found that the
USA and New Zealand were more likely to use crystal-
loids than colloids; whereas, countries like Australia,
China, Great Britain, Switzerland, and Sweden used
more colloids than crystalloids. Furthermore, the stron-
gest determinant of fluid choice was location of country,
not measures of illness severity in their patients. Al-
though we did not measure variations among geographic
regions of the USA, we did observe differences in fluid
Fig. 6 First choice of IV fluids for (a) patient type 1, (b) patient type
2, and (c) patient type 3 as reported by practice settings. “Albumin”
group includes 5 % albumin and 25 % albumin. “HES” group
includes HES 6 % 450/070, HES 6 % 600/0.75, and HES 6 % 130/0.4.
This dataset does not include physicians from Veterans Affairs
hospitals due to small sample (n = 13). Superscripts U and N denote
differences between practice settings that are statistically significant at
P < 0.05. HES, hydroxyethyl starch
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choice based on clinical practice settings. Physicians
from the nonuniversity hospitals preferred crystalloids
more than those from university hospitals for all 3 pa-
tient types (Fig. 6).
Specifically for patients with sepsis (patient type 3),
physicians from university hospitals were the more
likely to prefer albumin compared to physicians from
nonuniversity hospitals. Of interest for septic patients,
HES was chosen by 11 %–13 % of physicians (Fig. 6c);
this was unexpected because the use of HES in septic
patients does not align with SSC recommendations
(Dellinger et al. 2013). Based on results from the
VISEP (Brunkhorst et al. 2008), 6S (Perner et al.
2012), and CHEST (Myburgh et al. 2012) trials, the
SSC recommended against the use of HES. Instead,
fluid resuscitation in sepsis as defined by the SSC in-
cludes initial fluid challenge with crystalloids as the
first choice of fluid (grade 1B), followed by albumin
as the second choice if patients are unresponsive to
large amounts of crystalloids. When compared to
other fluid types, HES solutions, regardless of mo-
lecular weight, may be associated with increased mor-
tality and acute kidney injury in patients with sepsis
as well as in the general population (Myburgh et al.
2012; Brunkhorst et al. 2008; Guidet et al. 2012;
Schortgen et al. 2001; Zarychanski et al. 2013).
Table 2 Percent of physicians indicating crystalloids as first choice for volume expansion based on patient types
Practice settings
University hospital Nonuniversity hospital
(n = 138) (n = 351)
All clinical specialties n 138 364
Patient type 1 71.7 % 74.7 %
Patient type 2 45.7 % 61.5 %*
Patient type 3 64.5 % 73.6 %
Anesthesiologists only n 31 94
Patient type 1 74.2 % 79.8 %
Patient type 2 32.3 % 52.1 %*
Patient type 3 51.6 % 73.4 %*
Surgeons only n 35 90
Patient type 1 65.7 % 76.7 %
Patient type 2 45.7 % 66.7 %*
Patient type 3 60.0 % 73.3 %
Critical care medicine only n 33 71
Patient type 1 60.6 % 64.8 %
Patient type 2 42.4 % 59.2 %
Patient type 3 54.5 % 64.8 %
Pulmonologists only n 39 109
Patient type 1 84.6 % 75.2 %
Patient type 2 59.0 % 67.0 %
Patient type 3 87.2 % 79.8 %
Patient type 1: patient who needs volume expansion but is not bleeding and not septic. Patient type 2: patient who needs volume expansion in the presence of
blood loss when blood transfusion is not indicated (adequate Hb) and patient is not septic. Patient type 3: patient who needs volume expansion for resuscitation
in sepsis
*Statistically significant differences of P < 0.05 between practice settings within physician specialty
Table 3 Bolus volumes (mL) of fluid resuscitation with colloids vs crystalloids, by practice settings
University hospitals Nonuniversity hospitalsa
(n = 138) (n = 351)
Colloids (mL) Mean (SD) 411.8 (362.3) 485.5 (504.7)
Crystalloids (mL) Mean (SD) 716.5 (539.0) 821.7 (612.8)*
SD standard deviation
*Statistically significant differences of P < 0.05 between practice settings as analyzed by independent-sample t test
aExcludes physicians in Veterans Affairs hospital setting (n = 13)
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More physicians across all specialties chose colloid for
patients with blood loss (patient type 2) than for the
other 2 patient examples. Anesthesiologists preferred
more colloid, both 5 % albumin and HES, than physi-
cians from other specialties. This may be because anes-
thesiologists, relative to other specialists, are more
familiar with managing blood loss, when the faster speed
of shock reversal with colloid with less fluid volume re-
quired may be particularly advantageous (Rehm et al.
2000; Roger et al. 2014).
When asked about the importance of certain colloid
traits when colloids are used for volume expansion, 60 %
of physicians thought that the more sustained volume
expansion, faster volume expansion, and less interstitial
edema with colloids were either important or very im-
portant (Fig. 5), suggesting that physicians are generally
aware of the potential physiological advantages of col-
loids. Only 8 % of respondents thought that these prop-
erties were not important. With respect to the use of
albumin solutions as a specific type of colloid fluid, our
data aligns with previously published data from another
cross-sectional survey of 61 ICUs in Australia and New
Zealand between 2007 and 2013 (Hammond et al. 2015),
which found that hypo-oncotic albumin (31.6 %) was used
more frequently than hyper-oncotic albumin (11.6 %).
When comparing the fluid preference for resuscitation in
sepsis, our data showed that physicians in the USA pre-
ferred more crystalloids over colloids (Fig. 4).
Recent publications are calling for IV fluids to be con-
sidered as drugs and for physicians to approach fluid in-
fusions with the same considerations one would give for
the pharmacokinetic and pharmacodynamic characteris-
tics of any other treatment (Rewa and Bagshaw 2015;
McDermid et al. 2014; Santi et al. 2015; Severs et al.
2015). Furthermore, Bellomo and colleagues (Bellomo et
al. 2006) reported that fluid volume may be an inde-
pendent predictor of changes in pH, chloride, ionized
calcium, bicarbonate, base excess, and effective strong
ion difference within the first 24 h of resuscitation.
Our study revealed that physicians reported using a
wide range of fluid volumes for fluid boluses regardless
of clinical practice settings. Published evidence indicates
that initial high-volume fluid resuscitation is associated
with increased overall mortality in patients with trauma-
related bleeding (Wang et al. 2014) and that hyper-
oncotic albumin fluids are suitable for small-volume
resuscitation with no evidence of deleterious effects
(Jacob et al. 2008). Evidence from well-designed network
meta-analyses and clinical trials suggests that crystalloid
fluids, particularly balanced solutions, seem to be the
most advisable first choice, and albumin is equivalent or
superior to other available fluids in severe sepsis and
septic shock (Jacob et al. 2008; Rochwerg et al. 2015;
Rochwerg et al. 2014; Delaney et al. 2011; SAFE Study
Investigators et al. 2011). Altogether, the data from this
survey suggest that the participating physicians may pre-
fer albumin when a smaller bolus volume is desired to
achieve a more rapid and sustained volume expansion.
Thus in the context of sepsis, we believe it makes sense
that using small-volume fluid resuscitation, particularly
with colloids (e.g., albumin) early in the course of the
disease before significant EGL damage ensues, may be
better at limiting fluid loss into the interstitium, leading
to better intravascular volume expansion. Unfortunately,
our data do not explain how physicians would approach
the decision on bolus size based on the disease context.
The strength of this study is that it provides an up-to-
date picture of how fluid management is practiced in the
USA. Although a few international surveys on fluid re-
suscitation (McIntyre et al. 2007; Finfer et al. 2010;
Schortgen et al. 2004) have been conducted in the past,
major changes in fluid management have occurred in re-
cent years (Hammond et al. 2015), and past data may no
longer be relevant. For instance, we note that an older
survey conducted by the CRYCO Study Group in 2002
showed that colloids, not crystalloids, were widely
chosen as the first choice of fluid in Europe (Schortgen
et al. 2004), and starches were the most frequently used
colloids during that time. A limitation of this study is
that it describes current practices in only the USA. We
acknowledge that our study results cannot be general-
ized to other countries in the rest of the world. As our
study is based on a survey of physician preferences, we
did not report on clinical outcomes. We also recognize
that the decision-making processes of physicians are
complex and may vary from the situations we put forth
in the survey. While our study design cannot provide de-
tails for all of the reasons underlying treatment deci-
sions, the results allow physicians to compare their own
practice patterns to other colleagues, which could be
helpful given the lack of expert consensus on fluid resus-
citation in critically ill patients. It is also important to
provide basic background information for the design of
future trials that address complicated issues, such as
fluid resuscitation strategies. Although appropriate tim-
ing of fluid administration is an important topic, our
survey was not designed to delineate this matter; thus,
we cannot comment on how fluid resuscitation is influ-
enced by the temporal cadence of ICUs in the USA.
Based on the published literature, one could hypothesize
that early fluid therapy with colloids followed by a re-
stricted volume strategy may be associated with better
outcomes (van Haren and Zacharowski 2014), especially
in the context of sepsis (Lee et al. 2014).
Conclusions
This survey of physicians from different specialties car-
ing for patients in ICUs of the USA highlights several
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important issues in fluid resuscitation and fluid manage-
ment, which should be based on the underlying patho-
physiology of the disease context of the patient. Fluid
resuscitation is one component of a complex resuscita-
tion process with changing requirements over the dur-
ation of acute illness. However, estimating the extent of
hypovolemia or evaluating the response to a fluid chal-
lenge is difficult, as there is no single clinical or bio-
chemical parameter that reflects the complexity of the
circulation, particularly under rapidly changing patho-
logical conditions. With the lack of consensus, the physi-
cians in our study approached fluid resuscitation in a
wide variety of ways, depending on their clinical special-
ties and practice settings. It is important for physicians
to keep in mind the variability in fluid requirements of
each patient necessitates a targeted and integrated as-
sessment of volume status and on-going fluid needs
(Rewa and Bagshaw 2015). Crystalloid solution is the
primary fluid of choice for nonseptic and septic patients.
If physicians wish to use colloids in septic patients, then
according to the FDA and SSC recommendations albu-
min would be the logical second choice, not HES, due to
recent concerns about HES safety (U.S. Food and Drug
Administration 2013; Dellinger et al. 2013; Perner et al.
2012). In our survey, colloids were used more frequently
in the bleeding patient type, because physicians felt that
colloids provide more rapid and sustained volume ex-
pansion (Perner et al. 2012). We encourage physicians to
prescribe fluids as one would any other drug, carefully
considering the fluid amount, the fluid type, and the dis-
ease context specific to the patient being treated.
Additional files
Additional file 1: ICU Fluid Utilization Survey. (DOCX 308 kb)
Additional file 2: Figure S1. Fluid choices for patient who needs
volume expansion but is not bleeding and not septic (patient type 1). As
follow-up questions (for “Which of the following is your first choice for a
patient who needs volume expansion but is not bleeding and not septic?”),
the utilization frequency of (A) crystalloid, (B) 5 % albumin, (C) 6 % HES 450/
0.70 AND 6 % HES 600/0.75, and (D) 6 % HES 130/0.40 was assessed by
asking the question, “How often do you use each of the following in a
patient when volume expansion is indicated in the absence of blood loss
and sepsis?” N values for panels A–D are as follows: anesthesiologists
(n = 125), surgeons (n = 121), critical care medicine (n = 98), pulmonologists
(n = 146). Superscripts A, S, C, and P denote differences between specialties
that are statistically significant at P < 0.05. HES, hydroxyethyl starch.
(JPG 1674 kb)
Additional file 3: Figure S2. Fluid choices for patient who needs volume
expansion in the presence of blood loss when blood transfusion is not
indicated (adequate Hb) and patient is not septic (patient type 2). As
follow-up questions (for “Which of the following is your first choice for
a patient who needs volume expansion in the presence of blood loss
when blood transfusion is not indicated (adequate Hb) and patient is
not septic?”), the utilization frequency of (A) crystalloid, (B) 5 % albumin,
(C) 6 % HES 450/0.70 AND 6 % HES 600/0.75, and (D) 6 % HES 130/0.40
was assessed by asking the question, “How often do you use each of
the following in a patient for volume expansion in the presence of blood
loss when blood transfusion is not indicated (adequate Hb) and patient is
not septic?” N values for panels A–D are as follows: anesthesiologists
(n = 125), surgeons (n = 121), critical care medicine (n = 98), pulmonologists
(n = 146). Superscripts A, S, C, and P denote differences between specialties
that are statistically significant at P < 0.05. HES, hydroxyethyl starch.
(JPG 1692 kb)
Additional file 4: Figure S3. Fluid choices for patient who needs
volume expansion for resuscitation in sepsis (patient type 3). As follow-up
questions (for “Which of the following is your first choice for a patient who
needs volume expansion for resuscitation in sepsis?” As follow-up questions,
the utilization frequency of (A) crystalloid, (B) 5 % albumin, (C) 6 % HES 450/
0.70 AND 6 % HES 600/0.75, and (D) 6 % HES 130/0.40 was assessed by
asking the question, “How often do you use each of the following or a
patient who needs volume expansion for resuscitation in sepsis?” N values
for panels A–D are as follows: anesthesiologists (n = 125), surgeons (n = 120),
critical care medicine (n = 98), pulmonologists (n = 146). Superscripts A, S, C,
and P denote differences between specialties that are statistically significant
at P < 0.05. HES, hydroxyethyl starch. (JPG 1701 kb)
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